GSK plcGSKNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+3.1%
5Y CAGR+4.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+3.1%/yr
vs +53.3%/yr prior
5Y CAGR
+4.9%/yr
Consistent
Acceleration
-50.2pp
Decelerating
Percentile
P95
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 36.74% |
| Q4 2025 | -16.55% |
| Q2 2025 | 38.44% |
| Q1 2025 | -28.02% |
| Q4 2024 | 39.20% |
| Q3 2024 | -1.22% |
| Q2 2024 | 3.00% |
| Q1 2024 | -29.95% |
| Q4 2023 | 29.97% |
| Q3 2023 | 17.45% |
| Q2 2023 | 6.43% |
| Q1 2023 | -29.88% |
| Q4 2022 | 33.51% |
| Q3 2022 | 8.37% |
| Q2 2022 | 12.60% |
| Q1 2022 | -23.83% |
| Q4 2021 | 2.26% |
| Q3 2021 | 21.34% |
| Q2 2021 | 4.38% |
| Q1 2021 | -23.95% |
| Q4 2020 | 28.95% |
| Q3 2020 | -12.38% |
| Q2 2020 | 9.60% |
| Q1 2020 | -4.51% |
| Q4 2019 | 3.07% |
| Q3 2019 | 8.36% |
| Q2 2019 | 10.64% |
| Q1 2019 | -6.51% |
| Q4 2018 | 8.91% |
| Q3 2018 | 6.81% |
| Q2 2018 | 2.32% |
| Q1 2018 | -25.23% |
| Q4 2017 | 15.47% |
| Q3 2017 | -16.90% |
| Q2 2017 | 31.25% |
| Q1 2017 | -4.29% |
| Q4 2016 | 8.79% |
| Q3 2016 | 3.83% |
| Q2 2016 | 8.96% |
| Q1 2016 | -22.68% |